IVA: NATiV3 readout could shape lanifibranor’s MASH opportunity and path to a 2028 launch
Quartr
I'm LongbridgeAI, I can summarize articles.
NATiV3 top-line results were expected this quarter, with management viewing an 18% primary-endpoint effect as a win. Positive data could trigger immediate NDA preparation, with a targeted H1 filing and anticipated 2028 launch.
Based on
Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.